With $20 million raised in Series B financing, the developer of a metagenomics platform for microorganism detection plans to additional develop its technology—which might now detect novel coronavirus infection (2019-nCoV)—and develop its operations, together with a CLIA-permitted business laboratory on the firm’s Salt Lake City facility.
IDbyDNA stated proceeds from the financing are set for use towards advancing its next-generation sequencing (NGS)-based platform, designed to concurrently detect and analyze tens of 1000’s of microorganisms and pathogens in any pattern.
IDbyDNA markets the Explify® platform, designed to establish greater than 50,000 microorganisms, and greater than 3,000 recognized widespread and uncommon pathogens. The platform makes use of a proprietary database of curated DNA and RNA reference sequences to determine 35,000+ viruses, 13,000+ microorganisms, 4,000+ fungi, and 150+ parasites.
In response to the corporate, Explify presents customers safe information privacy, extremely curated and effectively-annotated databases, speedy metagenomic evaluation, QA/QC functions, customized consumer interfaces, and automatic report era instruments—with the platform’s newer options together with quantification and the power to detect antimicrobial resistance (AMR).
A model of the platform, Explify Respiratory, has lately been upgraded to allow it to detect 2019-nCoV, the coronavirus pressure found in Wuhan, China. It’s international unfold has generated 4,587 laboratory-confirmed instances of infection as of January 28, together with 106 deaths, based on the European Union’s European Centre for Illness Prevention and Control.
Explify customers embody hospital and reference labs, scientific analysis amenities, and biopharma. The corporate expects to additional ramp up its growth and advertising and marketing of the platform by a growth that’s anticipated to convey IDbyDNA to greater than 100 individuals from its present workforce of 70+ staffers—of which roughly 40 are primarily based at firm headquarters in San Francisco, and the remainder in Salt Lake Metropolis, Liao mentioned.
That development, in accordance with IDbyDNA, will come partly by serving what Liao stated was the numerous variety of hospitals that now have to send their samples for evaluation to outdoors labs as a result of they now lack in-house NGS evaluation capabilities.
Liao mentioned the financing would assist the corporate evolve from creating its Explify platform, having validated its expertise, to providing illness diagnostics which can be supposed to assist hospitals, reference labs, and different prospects considerably enhance the accuracy and velocity of microorganism detection.